Such approaches will be required to determine whether targeting G2A activity or its interaction with LPC in specific immunoregulatory cell types represents a viable approach to beneficially modulating inflammatory and immunological processes in the context of chronic inflammatory and autoimmune disease. This evidence concerns the gene GPR132 and autoimmune disease.